Celgene spondylitis drug misses main goal in late-stage study
July 9 (Reuters) - Celgene Corp said its experimental drug for the treatment of a type of arthritis that affects the spine failed to meet the main goal in a late-stage study, sending its shares down 3 percent premarket.
Patients suffering from ankylosing spondylitis who were treated with the drug, Otezla, failed to show statistically significant response compared to those on a placebo, the company said.
However, an independent data monitoring committee recommended that the study should continue unchanged. (Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)
- Ebola crisis turns a corner as U.S. issues new treatment protocols
- Total CEO de Margerie killed in Moscow business jet accident
- Obama makes rare campaign trail appearance, people leave early
- Apple's iPhone sales beat Street but iPad volumes slide
- UPDATE 1-Protesters decry Met Opera's 'Death of Klinghoffer' as anti-Semitic